Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Twitter summary: Using a #T2D therapy for #T1D, Lexicon & JDRF partner up for phase 2 trial of SGLT-2/SGLT-1 dual inhibitor drug On July 9, Lexicon announced a...
Twitter summary: Lilly’s new basal #insulin Peglispro superior to Sanofi’s Lantus in A1c reduction, though some potential liver safety and hypo concerns On September 4,...
On June 27, the FDA approved MannKind’s Afrezza for type 1 and type 2 diabetes, a new rapid-acting inhaled insulin. We’ve been following this story for years in diaTribe...
Twitter Summary: Novo Nordisk’s Xultophy gets positive recommendation in Europe, full approval to hopefully come soon! On July 25, Novo Nordisk announced that the...
Twitter summary: After huge anticipation for this innovative drug combination, Novo Nordisk’s Xultophy received approval in Europe for #T2D, 1 st ever basal insulin/GLP-...
On June 5, Xeris Pharmaceuticals announced that the first patient had been dosed in its phase 2 clinical trial , which is testing “mini-dose” glucagon for the treatment...
How many different factors can affect blood glucose? See the 22 things that can change your blood sugar in the short-term...
Twitter Summary: FDA approves Trulicity for #T2D, 1 st ready-to-use once-weekly GLP-1 agonist in the US, with a patient-friendly “auto-injector” – launch for later this...
On June 17, Boehringer Ingelheim (BI) and Lilly announced the resubmission to the FDA of the SGLT-2 inhibitor Jardiance (empagliflozin) for the treatment of type 2...
Twitter summary: FDA grants “tentative approval” to Lilly/BI’s Basaglar – new insulin option will be an alternative to Lantus in future On August 18, Eli Lilly and...
Twitter Summary: @LillyPad receives EU approval for Humalog 200 units/ml Kwikpen – 600 units of insulin in a 3 ml pen, hopeful US resubmission late 2014 Eli Lilly...
Debates in type 1 diabetes – what is the future of technology and what is a “cure"? Part three of our interview with David Panzirer and Dana Ball.
Twitter summary: New Sanofi & MannKind partnership to bring inhaled insulin Afrezza to US in early 2015, presumably primarily to type 2 patients to start On August...
Twitter summary: Roche’s Lucentis granted “priority review” from FDA – decision by Feb. 2015, potentially 1 st ever eye medicine for diabetic retinopathy Roche recently...
Advances in type 1 diabetes at The American Diabetes Association 74th Scientific Sessions
Twitter summary: FDA approves first-ever SGLT-2 inhibitor/metformin combo pill in the US – Janssens’s Invokamet launched Aug 18 On August 8, Janssen announced the FDA...
Twitter summary: Contrave launched in the US w/ weight support program + savings/loyalty programs offer new option for patients Two healthcare companies, Orexigen and...
On June 19, Novo Nordisk announced the launch of its FlexTouch pen for the long-acting basal insulin Levemir (insulin detemir). FlexTouch, which has been approved in...
Twitter summary: Exciting positive vote for #liraglutide #emdac on possible new therapy for #obesity! Plus, our favorite open public hearing yet. Yesterday on September...
Twitter summary: FDA approves Xigduo XR – first once-daily SGLT-2 inhibitor/metformin fixed dose combo in the US AstraZeneca recently announced that the FDA approved...

Pages